The LIPLEG Study in The Lancet: What the New Evidence Means for Lipedema Patients in the UK

Women with lipoedema often suffer not only from pain, tenderness, and physical limitations. Many patients also find it difficult to be taken seriously regarding their symptoms. Some wait years for the correct diagnosis or have to explain time and again to those around them that lipoedema is not merely a cosmetic issue.

The publication of the latest research on lipoedema in the renowned and most influential medical journal, The Lancet , is therefore encouraging: it represents exceptional international recognition for a condition that, for many years, has been under-researched, frequently overlooked, and underestimated in terms of its significance.

For affected women, treating doctors, and the entire lipoedema community, this publication is a scientific and health policy milestone. It is reshaping the discussion on what objectives modern lipoedema treatment should pursue and strengthens the foundation for better healthcare on an international scale.

Key Facts About the Published Study

This is the first large-scale, randomized, multicenter study: The published study enrolled 410 female patients with stage I through III lipedema of the legs at eleven study centers.

According to the study results, liposuction was significantly superior to conservative therapy: After twelve months, approximately 68% of the patients who underwent surgery achieved a clinically relevant reduction in pain, compared to approximately 8% in the group treated conservatively.
The results have already changed clinical practice: Based on the study data, the Joint Federal Committee decided to include liposuction in the standard coverage list of statutory health insurance, regardless of the stage of lipedema.
Key conclusion from The Lancet : “To date, liposuction is the only intervention with curative potential.”

Why a publication in The Lancet is so special

The Lancet is one of the oldest, best-known, and most influential medical journals in the world. Founded in 1823, the journal publishes internationally relevant research from nearly all fields of medicine.

A publication in The Lancet garners international attention. The findings published there are recognized worldwide by researchers, doctors, medical societies, and institutions. They can influence the further development of medical guidelines, treatment standards, and healthcare systems.

This is precisely why the publication on liposuction for lipedema is so significant: this chronic condition and its surgical treatment are no longer discussed only within a limited specialist community. They are reaching one of the most visible platforms in medicine worldwide.

Lipedema Study: What Was Published inThe Lancet?

In September 2026, two closely related articles appeared in The Lancet :

the scientific analysis of the LIPLEG study, titled
“Liposuction versus conservative therapy for patients with lipoedema in Germany: a multicentre, randomized controlled clinical trial”
the accompanying scholarly commentary
“Redefining treatment goals in lipoedema: the case for liposuction as a curative approach”

The clinical study presented there examines how effective liposuction is compared to continued conservative therapy. The accompanying commentary provides a professional analysis of the results and raises the fundamental question of whether treatment goals for lipedema need to change.

The LIPLEG Study: The First Large-Scale Randomized Comparison

Until now, much of the knowledge regarding surgical treatment for lipedema has been based on clinical experience and observational studies. These had already pointed to long-term improvements in pain and quality of life. What was missing, however, was a sufficiently large randomized controlled trial.

A total of 410 adult female patients participated in the LIPLEG study at eleven German study centers. All participants had been diagnosed with stage I, II, or III lipedema of the legs.

This group was randomly assigned to one of two groups:

278 patients underwent liposuction.
132 patients continued conservative therapy.

Twelve months after the last liposuction procedure or after random assignment, a clear difference emerged:

190 of 278 patients in the liposuction group achieved the treatment goal. This corresponds to approximately 68%.
In the conservatively treated control group, 10 out of 132 patients achieved the goal, or only about 8%.

The average trend in pain levels also differed significantly. In the liposuction group, leg pain tended to decrease, whereas in the conservatively treated group, the average pain level increased slightly.

The accompanying Lancet commentary makes a statement of extraordinary significance:

To date, liposuction is the only intervention with curative potential.

Implications for Lipedema Care Worldwide

But what does this publication mean for the future of lipedema treatment? The Lancet publication has the potential to change how lipedema is managed on several levels, including:

1. Greater visibility for the condition

A publication in a world-leading medical journal increases international awareness of lipedema. This is particularly important because many patients still face long waits for a correct diagnosis.

2. A new discussion on treatment goals

Care may evolve from exclusively symptom-oriented long-term management toward a strategy that specifically targets the pathologically increased adipose tissue in suitable patients.

3. Higher standards for treatment quality

As liposuction gains wider recognition, so does the responsibility to treat patients in specialized settings. What matters is not only whether surgery is performed, but also how careful diagnosis, planning, execution, and follow-up care are carried out.

What This Publication Means for Women with Lipedema

For women who have been battling lipedema for many years, the publication in The Lancet is much more than just scientific confirmation of their symptoms. Lipedema is a painful condition, not merely a cosmetic abnormality. Treatment must therefore be evaluated based on clinically relevant outcomes such as pain, mobility, and quality of life.

More importantly, however, the publication also reinforces the role of liposuction as a medically justified treatment option. For a long time, the primary focus was on the long-term management of symptoms through conservative measures. Patients were expected to learn to cope with the chronic condition and the treatment that is often required for life.

The publication of the new data opens up a broader perspective. For suitable patients, the treatment goal can go beyond temporary relief. Specifically, this means:

Liposuction and conservative therapy can be compared on a more sound basis.
The severity of symptoms takes center stage over purely cosmetic considerations.
Surgical treatment can now be considered regardless of the stage of the disease.
The decision should continue to be made on an individual basis, weighing the benefits against the risks.
The experience, specialization, and quality of care at the surgical facility remain essential.

This publication is therefore not a blanket promise that every liposuction procedure will result in the elimination of symptoms. However, it does provide very strong scientific evidence that the surgery can offer a clinically relevant benefit for appropriately selected patients.

Conclusion: Scientific Recognition Meets Specialized Treatment

The publication of the German LIPLEG study in The Lancet represents an extraordinary scientific milestone for lipedema treatment internationally.

For the first time, a large randomized, controlled, multicenter study shows that liposuction can be significantly superior to conservative therapy in terms of clinically relevant pain reduction. The accompanying commentary in the renowned medical journal also describes liposuction for lipedema as currently the only treatment with a potentially curative approach. This raises the fundamental question of whether treatment goals for lipedema need to be reoriented—away from long-term symptom management and toward a therapy that directly removes the pathologically increased adipose tissue.

For LIPOCURA®, this international recognition confirms just how important it is to have a scientifically sound and specialized surgical treatment for lipedema. At our specialized centers, patients are cared for by specialists who have in-depth expertise in the condition, its various manifestations, and the specific requirements of surgical treatment. In doing so, we consider not just individual areas of the body but the patient as a whole: from a detailed consultation and individualized surgical planning through safe procedure execution to structured postoperative care. The specialist consultation provides the appropriate framework for assessing the patient’s personal situation and determining the next steps in treatment.

The publication in The Lancet gives patients good reason for renewed confidence. At the same time, it underscores that scientific evidence, medical specialization, and high-quality standards go hand in hand. On this basis, we aim to responsibly translate these new findings into individualized lipedema treatment.

Schedule a consultation

Expert author

Dr. med. Katrin Lossagk

Dr. Katrin Lossagk has specialised in the surgical treatment of lipedema for many years and supports patients every step of the way, from accurate diagnosis through to personalised treatment and aftercare.

More about Dr. med. Katrin Lossagk